Post-polycythemia Vera Myelofibrosis
📧 Sign up to get email alerts when something new happens for Post-polycythemia Vera Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-04-30Clinical Trial Update: Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. [Phase 2]
Phase 2 trial update on the efficacy and safety of ruxolitinib in treating anemic myelofibrosis, with completed status and results posted.
-
CLINICAL_TRIALS trial_result · 2020-01-28Clinical Trial Update: Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) [Phase 2]
Phase 2 trial assessing ruxolitinib (INCB018424) in participants with primary myelofibrosis and related post-MPN myelofibrosis conditions ha…
-
CLINICAL_TRIALS trial_result · 2019-09-03Clinical Trial Update: Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF [Phase 2]
Phase II clinical trial update for INC424 (sonidegib) in various myelofibrosis subtypes has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-03-20Clinical Trial Update: Ruxolitinib Prior to Transplant in Patients With Myelofibrosis [Phase 2]
Phase 2 trial evaluating ruxolitinib before transplant in myelofibrosis was terminated; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-02-04Clinical Trial Update: Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) [Phase 2]
This is a Phase 2 extension study evaluating the long-term safety and efficacy of CYT387 (momelotinib) in patients with primary myelofibrosi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-02-04Clinical Trial Update: Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis [Phase 1, Phase 2]
A Phase 1/2 safety study evaluating twice-daily momelotinib in myelofibrosis populations has completed.
-
CLINICAL_TRIALS trial_result · 2019-02-01Clinical Trial Update: Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) [Phase 1, Phase 2]
This update reports the completion of a Phase 1/2 safety and efficacy study of CYT387 in primary myelofibrosis and myelofibrosis following p…
-
CLINICAL_TRIALS trial_result · 2018-04-02Clinical Trial Update: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib [Phase 2]
A Phase 2 trial of single-agent glasdegib in myelofibrosis patients previously treated with ruxolitinib was terminated; results were posted …
-
CLINICAL_TRIALS trial_result · 2017-04-24Clinical Trial Update: Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases [Phase 1]
A Phase 1 trial evaluating the safety of AZD1480 in adults with myeloproliferative diseases has completed, with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2016-07-11Clinical Trial Update: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis [Phase 3]
Phase 3 trial of ruxolitinib in primary myelofibrosis and related post-PV/post-ET myelofibrosis has completed, with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-05-23Clinical Trial Update: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET [Phase 2]
Phase 2 trial of the HSP90 inhibitor AUY922 in myeloproliferative neoplasms including primary myelofibrosis and MF after PV/ET was terminate…
-
CLINICAL_TRIALS trial_result · 2015-03-03Clinical Trial Update: Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) [Phase 4]
Completed Phase 4 exploratory study of INC424 (nilotinib) in patients with primary myelofibrosis or post-polycythemia vera myelofibrosis or …
-
CLINICAL_TRIALS trial_result · 2014-09-19Clinical Trial Update: Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis [Phase 2]
A Phase 2 trial investigates an alternative dosing strategy for ruxolitinib in myelofibrosis, with completed results posted in 2014.